AstraZeneca today announced that it has entered into a collaboration with Netherlands-based QIAGEN to develop a non-invasive diagnostic test to identify non-small cell lung cancer (NSCLC) patients who are suitable for treatment with IRESSA®.
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a clinical trial collaboration with Advaxis, Inc., a US-based biotechnology company developing cancer immunotherapies.
AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.
AstraZeneca today announced that the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 that current evidence from clinical studies does not support an accelerated approval for use of olaparib as a maintenance treatment for women with platinum-sensitive relapsed ovarian cancer who have the germline BRCA (gBRCA) mutation,
Platserna tog snabbt slut och väntelistorna är långa till AstraZenecas Sommarforskarskola 2014 som drar i gång idag. Intresset står i kontrast till den sedan länge förutspådda bristen på ingenjörer, tekniker och naturvetare de kommande åren.
AstraZeneca announced today that the majority of US Food and Drug Administration (FDA) Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) members voted that the FDA should not require cardiovascular outcomes trials for the peripherally-acting mu-opioid receptor antagonist (PAMORA) class of drugs, which includes MOVANTIKTM (naloxegol oxalate),
Phase IIa clinical study to commence in patients with severe asthma
Amgen and AstraZeneca today announced that results from a Phase II study evaluating brodalumab in 168 patients with psoriatic arthritis were published in The New England Journal of Medicine (NEJM).
43 abstracts on approved products and an investigational compound accepted for presentation First data from Phase III trial of saxagliptin/dapagliflozin combination presented as a late-breaker First six-year, open-extension to the DURATION-1 trial examining the efficacy and tolerability of exenatide will be presented
En ny undersökning med över 2 000 personer med typ 2-diabetes i Sverige visar att hela 52 procent av de som haft diabetes i mindre än tre år aldrig har fått utbildning om sin sjukdom. Jämfört med en tidigare undersökning pekar resultaten på en oroväckande trend; färre får utbildning, en större andel känner inte till sitt långtidsblodsocker och andelen som inte tar sin ordinerade medicin har ökat.
AstraZeneca provided an update on the rapid development of its oncology pipeline at a briefing for analysts and investors on 2 May 2014, as compelling data from over 40 scientific abstracts related to AstraZeneca and MedImmune investigational medicines were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
Pascal Soriot, Chief Executive Officer of AstraZenec
AstraZeneca today announced that the US Food and Drug Administration (FDA) has designated its novel investigational drug AZD0914 as a Qualified Infectious Disease Product (QIDP) and awarded its development programme Fast Track status for the treatment of uncomplicated gonorrhoea, which is increasingly resistant to existing antibiotics and poses a serious global public health threat.
